Idebenone

Research use only, not for human use.

Idebenone is a synthetic analog of coenzyme Q10 (CoQ10) and a brain stimulant.

Idebenone is a synthetic analog of coenzyme Q10 (CoQ10) and a brain stimulant.(In Vitro):Idebenone, a compound with protective efficacy against neurotoxicity both in in vitro and in in vivo models, exists in two different oxidative states: the ubiquinol-derivative (reduced idebenone) and the ubiquinone-derivative (oxidised idebenone).Idebenone (oxidised form) preferentially inhibits cyclooxygenase vs. lipoxygenase metabolism (IC50 ratio lipoxygenase/cyclooxygenase: 3.22).Idebenone (oxidised form) behaves similarly as indomethacin and piroxicam—two typical anti-inflammatory agents.Idebenone (oxidised form) inhibits total arachidonic acid metabolism, cyclooxygenase metabolism, lipoxygenase metabolism, lipoxygenase/cyclooxygenase with IC50s of 16.65±3.48, 14.44±2.99, 46.51±7.20, and 3.22 μM.Idebenone (1-10 μM; for 24-72 h) has no effect on the cell viability of SHSY-5Y cells.Idebenone (25 μM or higher concentrations; for 24-72 h) shows significant reduction in cell viability of SHSY-5Y cells. Idebenone (30 μM) induces up-regulation of BAX expression and the caspase-3 activity.(In Vivo):Idebenone (oxidised form) is a compound with protective efficacy against cerebrovascular disorders in vivo, including cerebral ischemia and hypertension-induced vascular lesions.

Idebenone, a compound with protective efficacy against neurotoxicity both in in vitro and in in vivo models, exists in two different oxidative states: the ubiquinol-derivative (reduced idebenone) and the ubiquinone-derivative (oxidised idebenone). Idebenone (oxidised form) preferentially inhibits cyclooxygenase vs. lipoxygenase metabolism (IC50 ratio lipoxygenase/cyclooxygenase: 3.22).Idebenone (oxidised form) behaves similarly as indomethacin and piroxicam—two typical anti-inflammatory agents.Idebenone (oxidised form) inhibits total arachidonic acid metabolism, cyclooxygenase metabolism, lipoxygenase metabolism, lipoxygenase/cyclooxygenase with IC50s of 16.65±3.48, 14.44±2.99, 46.51±7.20, and 3.22 μM.Idebenone (1-10 μM; for 24-72 h) has no effect on the cell viability of SHSY-5Y cells.Idebenone (25 μM or higher concentrations; for 24-72 h) shows significant reduction in cell viability of SHSY-5Y cells. Idebenone (30 μM) induces up-regulation of BAX expression and the caspase-3 activity. ell Viability Assay Cell Line:The human dopaminergic neuroblastma cell line, SHSY-5Y cells Concentration:1, 3, 10, 15, 25, 30, and 90 μM Incubation Time:24, 48, and 72 hours Result:Had no apparent detrimental effects on cell viability as indicated by the absence of trypan blue-positive staining in the cells at concentrations of 1, 3, 10 μM. Exhibited some degree of trypan blue-positive staining at 15 μM. Showed extensive trypan blue-positive staining at 25 μM and 30 μM. RT-PCR Cell Line:SHSY-5Y cells Concentration:10 μM, 30 μM Incubation Time:72 hours Result:The total RNA of BAX from SHSY-5Y cells exposed to 10 μM was not different from that of the untreated control cells. The BAX expression in SHSY-5Y cells exposed to 30 μM was significantly up-regulated when compared with the untreated control cells and cells exposed to 10 μM.

Idebenone (oxidised form) is a compound with protective efficacy against cerebrovascular disorders in vivo, including cerebral ischemia and hypertension-induced vascular lesions.

CV-2619 | Mnesis

Others

Antioxidant

Antioxidant

Cancer

——

58186-27-9

338.45

C19H30O5

>98% (HPLC)

Ethanol: 68 mg/mL (200.92 mM); DMSO: 68 mg/mL (200.92 mM)

O=C(C(OC)=C1OC)C(C)=C(CCCCCCCCCCO)C1=O

2-(10-Hydroxydecyl)-5,6-dimethoxy-3-methyl-p-benzoquinone

(-20℃)

With Ice Pack

≥ 2 years